Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial

Everhart JE, Lok AS, Kim HY, Morgan TR, Lindsay KL, Chung RT, et al. Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology. 2009;137(2):549-557.

Publication Type:

Journal Article

Authors:

Everhart, J.E.; Lok, A.S.; Kim, H.Y.; Morgan, T.R.; Lindsay, K.L.; Chung, R.T.; Bonkovsky, H.L.; Ghany, M.G.; HALT-C trial group

Source:

Gastroenterology, Volume 137, Issue 2, p.549-557 (2009)

Keywords:

Adult, Age Distribution, Aged, Antiviral Agents, Biopsy, Body Mass Index, Body Weight, Carcinoma, Comparative Study, complications, Confidence Intervals, Disease, Disease Progression, Dose-Response Relationship,Drug, Drug Administration Schedule, drug therapy, epidemiology, Fatty Liver, Female, Fibrosis, Follow-Up Studies, Health, hepatitis, Hepatitis C, Hepatitis C,Chronic, Homeostasis, Human, Humans, Incidence, Insulin, Insulin Resistance, Kidney, Kidney Diseases, Liver, Liver Cirrhosis, Long-Term Care, Male, Maryland, methods, Middle Aged, Obesity, pathology, Patients, prevention & control, Probability, Research, Research Support, resistance, Risk, Risk Assessment, Risk Factors, Severity of Illness Index, Sex Distribution, Survival Rate, therapeutic use, therapy, treatment, Treatment Outcome, Waist Circumference

Notes:

PMC3148692

Cited On:

When and in Whom to Initiate HCV Therapy

External Third-party Web Link:

http://www.ncbi.nlm.nih.gov/pubmed/19445938

Export Citation:

RIS Format

Top